Severe acute respiratory syndrome and coronavirus

David S C Hui, Paul K S Chan, David S C Hui, Paul K S Chan

Abstract

Severe acute respiratory syndrome (SARS) is a highly infectious disease with a significant morbidity and mortality. Respiratory failure is the major complication, and patients may progress to acute respiratory distress syndrome. Health care workers are particularly vulnerable to SARS. SARS has the potential of being converted from droplet to airborne transmission. There is currently no proven effective treatment of SARS, so early recognition, isolation, and stringent infection control are the key to controlling this highly contagious disease. Horseshoe bats are implicated in the emergence of novel coronavirus infection in humans. Further studies are needed to examine host genetic markers that may predict clinical outcome.

Copyright 2010 Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Thoracic HRCT of a patient with SARS showing typical early changes with solitary ground-glass opacification at the left lower lobe.

References

    1. Lee N., Hui D.S., Wu A. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994.
    1. Hsu L.Y., Lee C.C., Green J.A. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis. 2003;9:713–717.
    1. Booth C.M., Matukas L.M., Tomlinson G.A. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
    1. Twu S.J., Chen T.J., Chen C.J. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis. 2003;9:718–720.
    1. WHO Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Available at: Accessed September 23, 2003.
    1. Wang M., Yan M., Xu H. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis. 2005;11:1860–1865.
    1. Che X.Y., Di B., Zhao G.P. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003–2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis. 2006;43:e1–e5.
    1. Peiris J.S., Lai S.T., Poon L.L. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Kuiken T., Fouchier R.A., Schutten M. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–270.
    1. Drosten C., Gunther S., Preiser W. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
    1. Ksiazek T.G., Erdman D., Goldsmith C.S. A novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966.
    1. Fouchier R.A., Kuiken T., Schutten M. Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 2003;423:240.
    1. Rota P.A., Oberste M.S., Monroe S.S. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300:1394–1399.
    1. Marra M.A., Jones S.J., Astell C.R. The genome sequence of the SARS-associated coronavirus. Science. 2003;300:1399–1404.
    1. Ruan Y.J., Wei C.L., Ee L.A. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet. 2003;361:1779–1785.
    1. Du L., Qiu J.C., Wang M. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25:925–928.
    1. Guan Y., Zheng B.J., He Y.Q. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302:276–278.
    1. Song H.D., Tu C.C., Zhang Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005;102:2430–2435.
    1. Lau S.K., Woo P.C., Li K.S. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102:14040–14045.
    1. Li W., Shi Z., Yu M. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676–679.
    1. Shi Z., Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res. 2008;133:74–87.
    1. Zhao Z., Zhang F., Xu M. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52:715–720.
    1. Xu R.H., He J.F., Evans M.R. Epidemiologic clues to SARS origin in China. Emerg Infect Dis. 2004;10:1030–1037.
    1. Zhong N.S., Zheng B.J., Li Y.M. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in 2003. Lancet. 2003;362:1353–1358.
    1. Tsang K.W., Ho P.L., Ooi G.C. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1977–1985.
    1. Peiris J.S., Yuen K.Y., Osterhaus A.D. The severe acute respiratory syndrome. N Engl J Med. 2003;349:2431–2441.
    1. Wong R.S., Hui D.S. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis. 2004;10:339–341.
    1. Loon S.C., Teoh S.C., Oon L.L. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88:861–863.
    1. Yu I.T., Li Y., Wong T.W. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350:1731–1739.
    1. Chu C.M., Cheng V.C., Hung I.F. Viral load distribution in SARS outbreak. Emerg Infect Dis. 2005;11:1882–1886.
    1. Booth T.F., Kournikakis B., Bastien N. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis. 2005;191:1472–1477.
    1. Yu I.T., Wong T.W., Chiu Y.L. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis. 2005;40:1237–1243.
    1. Leung G.M., Hedley A.J., Ho L.M. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004;141:662–673.
    1. Hui D.S., Wong P.C., Wang C. Severe acute respiratory syndrome: clinical features and diagnosis. Respirology. 2003;8:S20–S24.
    1. Peiris J.S., Chu C.M., Cheng V.C. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767–1772.
    1. Leung W.K., To K.F., Chan P.K. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterologist. 2003;125:1011–1017.
    1. Chan H.L., Kwan A.C., To K.F. Clinical significance of hepatic derangement in severe acute respiratory syndrome. World J Gastroenterol. 2005;11:2148–2153.
    1. Hung E.C., Chim S.S., Chan P.K. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem. 2003;49:2108–2109.
    1. Lau K.K., Yu W.C., Chu C.M. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis. 2004;10:342–344.
    1. Wong K.C., Leung K.S., Hui M. Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg Am. 2003;85:1339–1342.
    1. Lee A.K., Oh H.M., Hui K.P. Atypical SARS in a geriatric patient. Emerg Infect Dis. 2004;10:261–264.
    1. Fisher D.A., Lim T.K., Lim Y.T. Atypical presentations of SARS. Lancet. 2003;361:1740.
    1. Hon K.L., Leung C.W., Cheng W.T. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003;561:1701–1703.
    1. Sit S.C., Yau E.K.C., Lam Y.Y. A young infant with severe acute respiratory syndrome. Pediatrics. 2003;112:e257–e260.
    1. Bitnun A., Allen U., Heurter H. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics. 2003;112:e261–e268.
    1. Chiu W.K., Cheung P.C., Ng K.L. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. Pediatr Crit Care Med. 2003;4:279–283.
    1. Wong S.F., Chow K.M., Leung T.N. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:292–297.
    1. Xu J.L., Qi X., Chi J. Orchitis: a complication of severe acute respiratory syndrome (SARS) Biol Reprod. 2006;74:410–416.
    1. Leung G.M., Lim W.W., Ho L.M. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect. 2006;134:211–221.
    1. Yu I.T., Xie Z.H., Tsoi K.K. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others? Clin Infect Dis. 2007;44:1017–1025.
    1. Hui D.S., Hall S.D., Chan M.T. Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest. 2007;132:540–546.
    1. Hui D.S., Chow B.K., Hall S.D. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest. 2009;135:648–654.
    1. Hui D.S., Hall S.D., Chan M.T. Non-invasive positive pressure ventilation: an experimental model to assess air and particle dispersion. Chest. 2006;130:730–740.
    1. Hui D.S., Chow B.K., Hall S.D. Exhaled air dispersion distances during application of non-invasive ventilation via different Respironics face masks. Chest. 2009;167:348–353.
    1. Hui D.S., Wong K.T., Antonio G.E. Severe acute respiratory syndrome (SARS): correlation of clinical outcome and radiological features. Radiology. 2004;233:579–585.
    1. Hui D.S., Sung J.J. Severe acute respiratory syndrome. Chest. 2003;124:12–15.
    1. Wong G.W., Hui D.S. Severe acute respiratory syndrome: epidemiology, diagnosis and treatment. Thorax. 2003;58:558–560.
    1. Wong R.S., Wu A., To K.F. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br Med J. 2003;326:1358–1362.
    1. Chen X., Zhou B., Li M. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189:1158–1163.
    1. Muller M.P., Tomlinson G., Marrie T.J. Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community acquired pneumonia? Clin Infect Dis. 2005;40:1079–1086.
    1. Lee N., Rainer T.H., Ip M. Role of laboratory variables in differentiating SARS-coronavirus from other causes of community-acquired pneumonia within the first 72 hrs of hospitalization. Eur J Clin Microbiol Infect Dis. 2006;25:765–772.
    1. Rainer T.H., Lee N., Ip M. Features discriminating SARS from other severe viral respiratory tract infections. Eur J Clin Microbiol Infect Dis. 2007;26:121–129.
    1. Wong K.T., Antonio G.E., Hui D.S. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 Patients. Radiology. 2003;228:401–406.
    1. Gomersall C.D., Joynt G.M., Lam P. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med. 2004;30:381–387.
    1. Wong K.T., Antonio G.E., Hui D.S. Thin section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology. 2003;228:395–400.
    1. Chan P.K., To K.F., Lo A.W. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol. 2004;74:1–7.
    1. Simmons G., Gosalia D.N., Rennekamp A.J. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005;102:11876–11881.
    1. Tripet B., Howard M.W., Jobling M. Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem. 2004;279:20836–20849.
    1. Hofmann H., Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol. 2004;12:466–472.
    1. Li W., Moore M.J., Vasilieva N. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454.
    1. Hamming I., Timens W., Bulthuis M.L. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–637.
    1. Tang J.W., To K.F., Lo A.W. Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. J Med Virol. 2007;79:1245–1253.
    1. Yang Z.Y., Huang Y., Ganesh L. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol. 2004;78:5642–5650.
    1. Gramberg T., Hofmann H., Möller P. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology. 2005;340:224–236.
    1. van Kooyk Y., Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol. 2003;3:697–709.
    1. Jeffers S.A., Tusell S.M., Gillim-Ross L. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2004;101:15748–15753.
    1. Marzi A., Gramberg T., Simmons G. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78:12090–12095.
    1. Lo A.W., Tang N.L., To K.F. How the SARS coronavirus causes disease: host or organism? J Pathol. 2006;208:142–151.
    1. Ng W.F., To K.F., Lam W.W. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1–a review. Hum Pathol. 2006;37:381–390.
    1. Gu J., Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170:1136–1147.
    1. Cameron M.J., Bermejo-Martin J.F., Danesh A. Human immunopathogenesis of severe acute respiratory syndrome (SARS) Virus Res. 2007;133:13–19.
    1. Guo Y., Korteweg C., McNutt M.A. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res. 2007;133:4–12.
    1. To K.F., Tong J.H., Chan P.K. Tissue and cellular tropisms of the coronavirus associated with severe acute respiratory syndrome-an in-situ hybridization study of fatal cases. J Pathol. 2004;202:157–163.
    1. Imai Y., Kuba K., Rao S. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116.
    1. Burrell L.M., Johnston C.I., Tikellis C. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15:166–169.
    1. Wong S.L., Chen Y., Chan C.M. In vivo functional characterization of the SARS-Coronavirus 3a protein in Drosophila. Biochem Biophys Res Commun. 2005;337:720–729.
    1. Law P.T., Wong C.H., Au T.C. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol. 2005;86:1921–1930.
    1. Tan Y.J., Fielding B.C., Goh P.Y. Over expression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol. 2004;78:14043–14047.
    1. Wong C.K., Lam C.W., Wu A.K. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136:95–103.
    1. Jiang Y., Xu J., Zhou C. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med. 2005;171:850–857.
    1. Huang K.J., Su I.J., Theron M. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75:185–194.
    1. Tang N.L., Chan P.K., Wong C.K. Early enhanced expression of IP-10 (CXCL-10) and other chemokines predict adverse outcome in severe acute respiratory syndrome (SARS) Clin Chem. 2005;51:2333–2340.
    1. Zhang Y., Li J., Zhan Y. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun. 2004;72:4410–4415.
    1. Lau Y.L., Peiris J.S. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol. 2005;17:404–410.
    1. Lin M., Tseng H.K., Trejaut J.A. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet. 2003;4:9.
    1. Ng M.H., Lau K.M., Li L. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis. 2004;190:515–518.
    1. Yuan F.F., Tanner J., Chan P.K. Influence of FcγRIIA and MBL polymorphisms on severe acute respiratory syndrome. Tissue Antigens. 2005;66:291–296.
    1. Yuan F.F., Boehm I., Chan P.K. High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus. Clin Vaccine Immunol. 2007;14:1644–1645.
    1. Ng M.W., Zhou G., Chong W.P. The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infect Dis. 2007;7:50.
    1. Chan V.S., Chan K.Y., Chen Y. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet. 2006;38:38–46.
    1. Tang N.L., Chan P.K., Hui D.S. Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection. Nat Genet. 2007;39:691–692.
    1. Zhi L., Zhou G., Zhang H. Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection. Nat Genet. 2007;39:692–694.
    1. Cinatl J., Morgenstern B., Bauer G. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361:2045–2046.
    1. Tan E.L., Ooi E.E., Lin C.Y. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10:581–586.
    1. Stroher U., DiCaro A., Li Y. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis. 2004;189:1164–1167.
    1. Sung J.J., Wu A., Joynt G.M. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 2004;59:414–420.
    1. Ng E.K., Ng P.C., Hon K.L. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem. 2003;49:2085–2088.
    1. Anand K., Ziebuhr J., Wadhwani P. Coronavirus main proteinase (3Clpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767.
    1. Chu C.M., Cheng V.C., Hung I.F. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252–256.
    1. Chan K.S., Lai S.T., Chu C.M. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J. 2003;9:399–406.
    1. Hurst M., Faulds D. Lopinavir. Drugs. 2000;60:1371–1381.
    1. Yamamoto N., Yang R., Yoshinaka Y. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318:719–725.
    1. Cinatl J., Morgenstern B., Bauer G. Treatment of SARS with human interferons. Lancet. 2003;362:293–294.
    1. Hensley L.E., Fritz L.E., Jahrling P.B. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis. 2004;10:317–319.
    1. Sainz B., Jr., Mossel E.C., Peters C.J. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Virology. 2004;329:11–17.
    1. Morgenstern B., Michaelis M., Baer P.C. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326:905–908.
    1. Chen F., Chan K.H., Jiang Y. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2005;39:69–75.
    1. Haagmans B.L., Kuiken T., Martina B.E. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004;10:290–293.
    1. Loutfy M.R., Blatt L.M., Siminovitch K.A. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA. 2003;290:3222–3228.
    1. Sui J., Li W., Murakami A. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101:2536–2541.
    1. ter Meulen J., Bakker A.B., van den Brink E.N. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004;363:2139–2141.
    1. Gao W., Tamin A., Soloff A. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362:1895–1896.
    1. Zhao P., Ke J.S., Qin Z.L. DNA vaccine of SARS-CoV S gene induces antibody response in mice. Acta Biochim Biophys Sin (Shanghai) 2004;36:37–41.
    1. Yang Z.Y., Kong W.P., Huang Y. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428:561–564.
    1. Ho T.Y., Wu S.L., Cheng S.E. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun. 2004;313:938–947.
    1. Bisht H., Roberts A., Vogel L. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A. 2004;101:6641–6646.
    1. Bukreyev A., Lamirande E.W., Buchholz U.J. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet. 2004;363:2122–2127.
    1. Bosch B.J., Martina B.E., van der Zee R. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A. 2004;101:8455–8460.
    1. Choy W.Y., Lin S.G., Chan P.K. Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development. Clin Chem. 2004;50:1036–1042.
    1. Ho J.C., Ooi G.C., Mok T.Y. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med. 2003;168:1449–1456.
    1. Tsang O.T., Chau T.N., Choi K.W. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis. 2003;9:1381–1387.
    1. Wang H., Ding Y., Li X. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349:507–508.
    1. Hong N., Du X.K. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol. 2004;59:602–608.
    1. Griffith J.F., Antonio G.E., Kumta S.M. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology. 2005;235:168–175.
    1. Lee N., Allen Chan K.C., Hui D.S. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309.
    1. Cheng Y., Wong R., Soo Y.O. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
    1. Soo Y.O., Cheng Y., Wong R. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676–678.
    1. Liu B.Y., Hu J.Q., Xie Y.M. Effects of integrative Chinese and Western medicine on arterial oxygen saturation in patients with severe acute respiratory syndrome. Chin J Integr Med. 2004;10:117–122.
    1. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol. 1997;100:151–157.
    1. Lew T.W., Kwek T.K., Tai D. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:374–380.
    1. Chong P.Y., Chui P., Ling A.E. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med. 2004;128:195–204.
    1. Umapathi T., Kor A.C., Venketasubramanian N. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS) J Neurol. 2004;251:1227–1231.
    1. Ho J.C., Wu A.Y., Lam B. Pentaglobulin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis. 2004;8:1173–1179.
    1. Ng K.H., Wu A.K., Cheng V.C. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J. 2005;81:e3.
    1. Dalakas M.C., Clark W.M. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology. 2003;60:1763–1767.
    1. Chen L., Liu P., Gao H. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis. 2004;39:1531–1535.
    1. Akerstrom S., Mousavi-Jazi M., Klingstrom J. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005;79:1966–1969.
    1. WHO SARS case fatality ration, incubation period. Available at: Accessed May 23, 2005.
    1. Donnelly C.A., Ghani A.V., Leung G.M. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 2003;361:1761–1766.
    1. Tsui P.T., Kwok M.L., Yuen H. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis. 2003;9:1064–1069.
    1. Chan J.W., Ng C.K., Chan Y.H. Short term outcome and risk factors for adverse clinical outcomes in adults with Severe acute respiratory syndrome (SARS) Thorax. 2003;58:686–689.
    1. Chu C.M., Poon L.L., Cheng V.C. Initial viral load and the outcomes of SARS. CMAJ. 2004;171:1349–1352.
    1. Hui D.S., Joynt G.M., Wong K.T. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60:401–409.
    1. Hui D.S., Wong K.T., Ko F.W. The one-year impact of severe acute respiratory syndrome (SARS) on pulmonary function, exercise capacity and quality of life in a cohort of survivors. Chest. 2005;128:2247–2261.
    1. Tsai L.K., Hsieh S.T., Chao C.C. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol. 2004;61:1669–1673.
    1. Yu W.C., Hui D.S., Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of SARS. Thorax. 2004;59:643–645.
    1. Tsang K.W., Ooi G.C., Ho P.L. Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt? Eur Respir J. 2004;24:1025–1032.
    1. Ong K.C., Ng A.W., Lee L.S. 1-year pulmonary function and health status in survivors of severe acute respiratory syndrome. Chest. 2005;128:1393–1400.
    1. Xie L., Liu Y., Xiao Y. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest. 2005;127:2119–2124.
    1. Tansey C.M., Louie M., Loeb M. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med. 2007;167:1312–1320.
    1. Chua S.E., Cheung V., McAlonan G.M. Stress and psychological impact on SARS patients during the outbreak. Can J Psychiatry. 2004;49:385–390.
    1. Cheng S.K., Wong C.W., Tsang J. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS) Psychol Med. 2004;34:1187–1195.
    1. Lee D.T., Wing Y.K., Leung H.C. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis. 2004;39:1247–1249.
    1. Chen Z., Zhang L., Qin C. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005;79:2678–2688.
    1. He Y., Li J., Heck S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006;80:5757–5767.
    1. Weingartl H., Czub M., Czub S. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78:12672–12676.
    1. Petersen N.C., Boyle J.F. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res. 1980;41:868–876.
    1. Vennema H., de Groot R.J., Harbour D.A. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64:1407–1409.
    1. Chan P.K., Ip M., Ng K.C. Severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect Dis. 2003;9:1453–1454.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa